Misyo (Methadone Hydrochloride)

Methadone works by binding to µ‑opioid receptors in the brain and spinal cord, acting as a full agonist. This activation produces analgesia and suppresses withdrawal symptoms. Additional actions include NMDA receptor antagonism and inhibition of serotonin and norepinephrine reuptake, which enhance its therapeutic profile.

The appropriate dose of Misyo is individualized and set by a qualified prescriber based on the patient’s clinical condition, prior opioid exposure, and response to therapy. Dosing regimens are tailored during treatment initiation and adjusted as needed.

Methadone is classified as Pregnancy Category C, indicating that it should be used only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so breastfeeding decisions should be made in consultation with a healthcare professional.

To order Misyo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Methadone, the active ingredient in Misyo, offers a longer half‑life than short‑acting opioids like morphine, allowing once‑daily dosing for maintenance therapy. Compared with buprenorphine, methadone provides full µ‑receptor agonism, which can be advantageous for patients with high opioid tolerance, though it requires more stringent monitoring.

Misyo should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Misyo is administered orally, typically as a tablet or liquid formulation, as directed by the prescribing clinician. The exact route (swallow whole, dissolve, or mix with food) depends on the specific product presentation and the patient’s ability to take oral medication.

The most serious risks include respiratory depression, which can be life‑threatening, especially during dose escalation or when combined with other CNS depressants. Cardiac effects such as QT interval prolongation and severe hypotension are also critical concerns that require monitoring.

Misyo should be avoided in patients with known hypersensitivity to methadone, severe respiratory insufficiency, uncontrolled cardiac arrhythmias, or those taking contraindicated medications that could cause dangerous interactions. Clinicians must assess each patient’s medical history before initiating therapy.